

Literatur:

1. European Commission. Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products. 2000 S. L18:1-5. Report No.: 141/2000.
2. European Medicines Agency. Rare diseases. 2023.
3. Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. *Nat Rev Genet.* Oktober 2013;14(10):681–91.
4. Braun MM, Farag-El-Massah S, Xu K, Coté TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. *Nat Rev Drug Discov.* Juli 2010;9(7):519–22.
5. Advanced therapy medicinal products: Overview | European Medicines Agency (EMA) [Internet]. 2010 [zitiert 1. Februar 2026]. Verfügbar unter: <https://www.ema.europa.eu/en/human-regulatory-overview/advanced-therapy-medicinal-products-overview>
6. Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming Challenges Facing Advanced Therapies in the EU Market. *Cell Stem Cell.* 1. September 2016;19(3):293–7.
7. Storch K, Dinger J, von der Hagen M. Differenzialdiagnose der muskulären Hypotonie bei Neugeborenen. *Neonatalogie Scan.* 2023;25(7):153–79.
8. Prasad AN, Prasad C. Genetic evaluation of the floppy infant. *Semin Fetal Neonatal Med.* April 2011;16(2):99–108.
9. Klein A, Boltshauser E. „Floppy Baby“. *Pädiatrie up2date.* Dezember 2011;6(04):371–86.
10. Dubowitz L. The floppy infant. London: Mac Keith Press; 1998.
11. Bodensteiner JB. The evaluation of the hypotonic infant. *Semin Pediatr Neurol.* März 2008;15(1):10–20.
12. Cutrona C, Pede E, De Sanctis R, Coratti G, Tiberi E, Luciano R, u. a. Assessing floppy infants: a new module. *Eur J Pediatr.* Juli 2022;181(7):2771–8.
13. Laugel V, Cossée M, Matis J, de Saint-Martin A, Echaniz-Laguna A, Mandel JL, u. a. Diagnostic approach to neonatal hypotonia: retrospective study on 144 neonates. *Eur J Pediatr.* Mai 2008;167(5):517–23.
14. Jiménez E, García-Cazorla A, Colomer J, Nascimento A, Iriondo M, Campistol J. [Hypotonia in the neonatal period: 12 years' experience]. *Rev Neurol.* 16. Januar 2013;56(2):72–8.
15. Vasta I, Kinali M, Messina S, Guzzetta A, Kapellou O, Manzur A, u. a. Can clinical signs identify newborns with neuromuscular disorders? *J Pediatr.* Januar 2005;146(1):73–9.
16. Kowalczyk B, Feluś J. Arthrogryposis: an update on clinical aspects, etiology, and treatment strategies. *Arch Med Sci.* 1. Februar 2016;12(1):10–24.
17. Hall JG. Arthrogryposis multiplex congenita: etiology, genetics, classification, diagnostic approach, and general aspects. *J Pediatr Orthop B.* Juli 1997;6(3):159–66.
18. Dubowitz L, Mercuri E, Dubowitz V. An optimality score for the neurologic examination of the term newborn. *J Pediatr.* September 1998;133(3):406–16.
19. [springermedizin.de](http://springermedizin.de) [Internet]. [zitiert 26. Februar 2022]. Diagnostik von Myopathien bei Kindern und Jugendlichen. Verfügbar unter: <https://www.springermedizin.de/neuromuskulaere-erkrankungen-bei-kindern/untersuchung-des-neugeborenen/diagnostik-von-myopathien-bei-kindern-und-jugendlichen/19719566>
20. Saudubray JM, Baumgartner MR. Inborn Metabolic Diseases: Diagnosis and Treatment. 6. Aufl. Springer; 2016.
21. Prasad AN, Prasad C. The floppy infant: contribution of genetic and metabolic disorders. *Brain Dev.* Oktober 2003;25(7):457–76.
22. Zschocke H, Hoffmann GF. *Vademecum Metabolicum: Diagnose und Therapie erblicher Stoffwechselkrankheiten.* 4. Aufl. Thieme; 2021.
23. Prasad AN, Prasad C. Genetic evaluation of the floppy infant. *Semin Fetal Neonatal Med.* April 2011;16(2):99–108.
24. Sharma S, Repnikova E, Noel-MacDonnell JR, LePichon JB. Diagnostic yield of genetic testing in 324 infants with hypotonia. *Clin Genet.* Dezember 2021;100(6):752–7.
25. Paro-Panjan D, Neubauer D. Congenital hypotonia: is there an algorithm? *J Child Neurol.* Juni 2004;19(6):439–42.
26. AWMF. AWMF-S2k-Leitlinie Neugeborenen-Screening auf angeborene Stoffwechselstörungen, Endokrinopathien, SCID, Sichelzellerkrankheit und 5q-assoziierte SMA. Report No.: Register Nr. 024-012. 2025.
27. Wolf B. Biotinidase deficiency: „if you have to have an inherited metabolic disease, this is the one to have“. *Genet Med.* Juni 2012;14(6):565–75.
28. Pane M, Donati MA, Cutrona C, De Sanctis R, Pirinu M, Coratti G, u. a. Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. *Eur J Pediatr.* 6. Mai 2022;
29. van Trotsenburg P, Stoupa A, Léger J, Rohrer T, Peters C, Fugazzola L, u. a. Congenital Hypothyroidism: A 2020-2021 Consensus Guidelines Update-An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology. *Thyroid.* März 2021;31(3):387–419.
30. Butler MG, Miller JL, Forster JL. Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update. *Curr Pediatr Rev.* 2019;15(4):207–44.
31. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, u. a. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. *Neurology.* 9. Januar 2007;68(2):99–109.
32. van der Beek NAME, Theunissen MTM, van den Hout JMP, Pijnappel WWM, Schoser B, Laforêt P, u. a. Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease. *Lancet Neurol.* März 2025;24(3):230–45.
33. Schwartz O, Vill K, Pfaffenlehner M, Behrens M, Weiß C, Johannsen J, u. a. Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial. *JAMA Pediatr.* 1. Juni 2024;178(6):540–7.
34. Müller-Felber W, Blaschek A, Schwartz O, Gläser D, Nennstiel U, Brockow I, u. a. Newbornscreening SMA - From Pilot Project to Nationwide Screening in Germany. *J Neuromuscul Dis.* 2023;10(1):55–65.
35. Hipp JF, Bacino CA, Bird LM, Bruenig-Traebert I, Chan D, de Wit MC, u. a. The UB3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial. *Nat Med.* September 2025;31(9):2936–45.
36. Wang SE, Jiang YH. Novel epigenetic molecular therapies for imprinting disorders. *Mol Psychiatry.* August 2023;28(8):3182–93.
37. Jensen TL, Göttsche CR, Woldbye DPD. Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord. *Front Mol Neurosci.* 2021;14:695937.
38. Novak I, Morgan C, Fahey M, Finch-Edmondson M, Galea C, Hines A, u. a. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. *Curr Neurol Neurosci Rep.* 21. Februar 2020;20(2):3.
39. Verschuren O, Peterson MD, Balemans ACJ, Hurvitz EA. Exercise and physical activity recommendations for people with cerebral palsy. *Dev Med Child Neurol.* August 2016;58(8):798–808.
40. Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, u. a. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. *Neuromuscul Disord.* März 2018;28(3):197–207.
41. Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, u. a. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol.* April 2018;17(4):347–61.
42. Mink J, Sanger T, Jackson J, et al. Evidence-based review of pharmacologic treatment of childhood dystonia. *Mov Disord.* 2006;21(12):2066-2074.
43. Roubertie A, Mariani LL, Fernández-Alvarez E, Doummar D, Roze E. Treatment for dystonia in childhood. *European journal of neurology : the official journal of the European Federation of Neurological Societies.* 31. Januar 2012;19:1292–9.
44. Novak I, Honan I. Effectiveness of paediatric occupational therapy for children with disabilities: A systematic review. *Aust Occup Ther J.* Juni 2019;66(3):258–73.
45. Kuperminc MN, Stevenson RD. Growth and nutrition disorders in children with cerebral palsy. *Dev Disabil Res Rev.* 2008;14(2):137–46.
46. Lefton-Greif MA, Arvedson JC. Pediatric Feeding/Swallowing: Yesterday, Today, and Tomorrow. *Semin Speech Lang.* November 2016;37(4):298–309.
47. Metzler S, Brown GR. A review of Prader-Willi syndrome. *JAAPA.* 1. Februar 2025;38(2):e1–6.
48. Rellensmann G, Hasan C. *Advance Care Planning- Vorrasschauende Versorgungsplanung.* 3. Auflage. Berlin, Heidelberg: Springer; 2021. 79–112 S.
49. AWMF S2k-Leitlinie: Palliativmedizin für Kinder und Jugendliche. 2020.
50. Craig F, Huijjer HAS, Benini F, Kuttner L, Wood C, Ferraris FP, u. a. IMPaCCT: Standards pädiatrischer Palliativversorgung in Europa. *Zeitschrift für Palliativmedizin.* Juni 2008;9(2):61–6.